Risankizumab Shows Comparable Safety and Efficacy Profiles in Patients With Psoriasis

Risankizumab, guselkumab, and tildrakizumab showed similar efficacy and safety profiles, according to results from a recent study published in the Journal of Dermatological Treatment.

Researchers aimed to perform a real-life study to compare indirect efficacy and safety of anti-IL23s, specifically focusing on difficult-to-treat areas in a 2-year, single-center, retrospective observational study in patients with moderate to severe psoriasis. Clinical and demographic data were collected at baseline and weeks 4, 16, and 28. Psoriasis Area and Severity Index (PASI), body surface area (BSA), Nail Psoriasis Severity Index, and specific BSA were evaluated in a total of 150 patients. Patients received either guselkumab, tildrakizumab, or risankizumab.

The 3 groups were comparable for age, sex, and disease severity. Differences between the 3 groups were shown in psoriasis duration, psoriatic arthritis prevalence, and previous systemic treatment failure. All 3 drugs similarly reduced mean PASI and BSA from baseline up to week 28. PASI 100 was reached by 73.4% to 85% of the patients and all drugs showed high efficacy.

“Our 28-weeks study demonstrated a comparable efficacy and safety profile for all anti-IL23[s], with guselkumab and risankizumab appearing slightly faster than tildrakizumab particularly on palmoplantar lesions in the short-term,” concluded the study authors.

Reference
Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. Published online May 29, 2022. doi:10.1080/09546634.2022.2081655